See how your reported results read as versioned evidence records β linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review claims
Explore by Goal
"Science is the acceptance of what works and the rejection of what does not. That needs more courage than we might think."
- Jacob Bronowski
Quick Explanation
Copied
Concise author snapshot β Steffen Pockes
Steffen Pockes is an active medicinal/chemical-biological researcher (multiple GPCR/receptorβbiochemistry papers; coauthor on high-quality journals including ACS Chemical Neuroscience, Journal of Medicinal Chemistry, Scientific Reports, and Nature Communications). His work emphasizes histamine receptor ligands, radioligands, NanoBRET assays, and GPCR functional tools β papers show substantive experimental depth and tool development for H2/H3 receptors
Visualizations first β key signals from publication record and topic focus (GPCR ligand design, histamine H2/H3 receptors, radioligands, NanoBRET/functional biosensors, cryo-EM coauthorship).
What the data visually shows
Active, focused portfolio: steady output across 2018β2024 with peaks in 2020β2023 (tool development and multiple openβaccess papers) β supports a sustained research program in GPCR ligand/biosensor chemistry.
High-impact tools & assays: coauthorship on NanoBRET and radioligand tool papers used by GPCR field (Journal of Medicinal Chemistry, Scientific Reports, ACS Chemical Neuroscience, Nature Communications) β indicates methodological contributions across ligand design and receptor pharmacology
Strengths (evidence-based)
Consistent coauthorship on experimental papers using modern receptor pharmacology methods (NanoBRET, mini-G, Ξ²βarrestin, kinetic radioligand assays) β indicates strong experimental competence with both chemistry and cellβbased pharmacology .
Collaborations with established GPCR labs (e.g., Lohse group, Max DelbrΓΌck Center; coauthorship on cryoβEM H2R/Gs structure paper suggests participation in high-end structural biology projects) .
Limitations, blind spots and potential biases
Many papers are collaborative and Pockes is frequently a middle/last author; attributing leadership vs technical contribution requires inspection of author position and contributions per paper (not all entries show corresponding author or PI role).
Field reliance on recombinant systems and in vitro assays β common limitation in pharmacology: activity measured in HEK293T/Sf9 membranes and ex vivo tissues may not fully predict in vivo therapeutic effects; several papers explicitly note cross-species and system-dependent variability in bias metrics .
OpenAlex shows a moderate h-index (~14) and ~53 works with ~581 citations (summary data provided in the prompt). While respectable for a midβcareer researcher, it is not yet at senior 'fieldβlead' citation density; signal indicates strong technical contributions and tool papers rather than many high-citation single-author theoretical breakthroughs.
Possible publication bias toward tool/method papers (NanoBRET, radioligands) which are highly useful but can attract citations for the tool rather than conceptual novelty; this inflates apparent impact while still being valuable.
Concrete, evidence-based recommendations for interpreting Pockes's work
When using his coauthored tools (e.g., fluorescent ligands, radioligands), read methods/SI carefully β bias analyses and kinetic fits are often in supporting information and include species/system caveats .
To assess leadership contribution, inspect corresponding author and contribution statements in each paper (many high-quality methods papers distribute credit across chemistry and biology labs).
For translational claims, prefer studies with in vivo validation; current corpus emphasizes in vitro/ex vivo tools, which are necessary but not sufficient for therapeutic claims.
Representative highβvalue papers (selected with short rationale)
Tool development & imaging: UR-NR266 fluorescent H3R ligand β robust NanoBRET + singleβmolecule demonstration (Journal of Medicinal Chemistry)
Assay methodology: Live-cell NanoBRET H2R binding assay for kinetic and affinity data (Scientific Reports) β useful for live-cell pharmacology comparisons
Structural biology contribution: Coauthorship on H2R/Gs cryo-EM structure (Nature Communications 2024) β indicates participation in high-level structural projects that strengthen molecular interpretation of ligand effects
Bottom-line evaluation (evidence-weighted)
Steffen Pockes is a technically strong, methodologically broad researcher whose work reliably produces experimental tools and assays used in GPCR/histamine receptor research. Evidence shows multi-disciplinary competence (medicinal chemistry, radiochemistry, liveβcell NanoBRET, biosensors, and structural collaborations). The corpus favors experimental tool and assay development with rigorous methods and transparent SI; translational claims beyond in vitro/ex vivo systems are limited in the current corpus and should be assessed case-by-case with follow-up in vivo validation.
Key evidence citations referenced above
Next steps / actions: (1) Inspect contribution statements for leadership roles; (2) Use tools (URβNR266, [3H]23) with SI-provided protocols and cross-validate in your system; (3) For translational work, require independent in vivo validation before concluding therapeutic relevance.
Feedback:
Updated: March 18, 2026
BGPT Author Review
Scientific Quality
70%
Steffen Pockes demonstrates strong experimental competence across medicinal chemistry, radiochemistry, and GPCR pharmacology with multiple tool papers and a solid citation footprint; however many contributions are collaborative and focused on assay/tool development rather than large, singular conceptual breakthroughs, placing him above mid-career competence but below top-field leaders.
Communication Quality
70%
Papers are published in clear, method-focused journals with thorough supporting information; experimental details and SI are thorough, but narrative novelty is often incremental and targeted to specialist audiences rather than broad conceptual exposition.
Author Novelty
60%
Novelty is moderate-to-high in tool and ligand design (e.g., fluorescent NanoBRET ligands, radioligands showing G protein bias), but the corpus emphasizes method/assay innovation and incremental SAR rather than paradigm-shifting theory.
Scientific Rigor
80%
High methodological rigor: validated synthetic characterization (NMR/HRMS), kinetic binding fits, bias quantification, ortholog testing, and cryo-EM participation indicate reproducible, rigorous experimental practice; main caveat is dependence on in vitro/ex vivo systems for many conclusions.
Parsing OpenAlex counts_by_year and plotting publication and citation trends to quantify year-on-year productivity and citation impact for Pockes.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Hypothesis: Pockes is primarily a medicinal-chemistry-only researcher β falsified because multiple coauthored papers demonstrate cell-based assays, NanoBRET, and cryo-EM collaboration.
Hypothesis: His outputs lack reproducibility β not supported; many papers include SI with raw data and method details facilitating replication.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
Keep Exploring
